TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22436841

Group type: EXPERIMENTAL
Intervention: Endurance training (T)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Energy-reduced diet (D)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Training and increased diet (T-iD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study: 20507600

Group type: EXPERIMENTAL
Intervention: Dutch patient advocacy case management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18779444

Group type: EXPERIMENTAL
Intervention: ST-segment recovery measurement in the most affected lead on the post-PCI ECG
Number of subjects: 4866
Study: 15727161

Group type: EXPERIMENTAL
Intervention: Vertigoheel® (VH)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Control treatment (betahistine, Ginkgo biloba extract, dimenhydrinate)
Number of subjects: 1388
Study: 15537696

Group type: EXPERIMENTAL
Intervention: miconazole and rifampicin modified catheter (n=118)
Number of subjects: 223

Group type: COMPARATOR
Intervention: standard triple-lumen CVC (n=105)
Number of subjects: 223
Study: 11273927

Group type: EXPERIMENTAL
Intervention: Preemptive IA Morphine (3 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postoperative IA Morphine (3 mg)
Number of subjects: 40
Study: 9423805

Group type: EXPERIMENTAL
Intervention: S-nitrosoglutathione (GSNO) 50 microg/min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no GSNO)
Number of subjects: 12
Study: 8491304

Group type: EXPERIMENTAL
Intervention: Acetazolamide, 750 mg daily for 2 days before the ascent and on the first day at altitude (3,200 m)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no acetazolamide)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acetazolamide group (T)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 16
Study: 3022035

Group type: EXPERIMENTAL
Intervention: Continuous regimen (cyclophosphamide, oncovin, nimustine hydrochloride, procarbazine - CONP) every four weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Alternating regimen (CONP alternating with etoposide, adriamycin, cisplatin - VAD at four-week intervals)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall response rates
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Projected median survival times
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Survival beyond two years
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Major toxicity
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Death due to treatment
Number of subjects: 69
Study: 27393706

Group type: EXPERIMENTAL
Intervention: Student self-assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Faculty assessment
Number of subjects: 0
Study: 27030661

Group type: EXPERIMENTAL
Intervention: High expectations of recovery
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Moderate expectations of recovery
Number of subjects: 716

Group type: COMPARATOR
Intervention: Low expectations of recovery
Number of subjects: 716
Study: 24213216

Group type: EXPERIMENTAL
Intervention: Once-weekly teriparatide (56.5 μg for 72 weeks)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 22695789

Group type: EXPERIMENTAL
Intervention: Community falls prevention service
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual health and social care
Number of subjects: 157
Study: 20554120

Group type: EXPERIMENTAL
Intervention: ANP infusion at the beginning of the 1st half of the night
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP infusion at the beginning of the 2nd half of the night
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study: 18242724

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated migraineurs
Number of subjects: 0
Study: 16828095

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (25 mug every 6 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 mug every 6 hours)
Number of subjects: 150
Study: 12681024

Group type: EXPERIMENTAL
Intervention: Single-tablet metformin-glibenclamide combination therapy (Glucovance®)
Number of subjects: 1856

Group type: COMPARATOR
Intervention: Metformin 500 mg and glibenclamide 2.5‐5 mg monotherapy
Number of subjects: 1856
Study: 11015699

Group type: EXPERIMENTAL
Intervention: Numerical probability presentation (e.g. 1:650 chance)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Verbal probability presentation (e.g. 'your chance is low')
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Numerical probability presentation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Verbal probability presentation
Number of subjects: 220
Study: 1452619

Group type: EXPERIMENTAL
Intervention: 20 mg of timolol (oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol as internal standard
Number of subjects: 0
Study: 3867354

Group type: EXPERIMENTAL
Intervention: Cicletanine 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cicletanine 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cicletanine (single and 14-day regimens)
Number of subjects: 0
Study: 31371810

Group type: EXPERIMENTAL
Intervention: Miso group (32 g 2:1 w/w Nenrin and MK‐34‐1 with 3.8 g salt/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control soy food group (14.4 g soy food with 0.2 g salt/day)
Number of subjects: 40
Study: 29431535

Group type: EXPERIMENTAL
Intervention: Low-energy breakfast (205 kcal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-energy breakfast (570 kcal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Active participants
Number of subjects: 16

Group type: COMPARATOR
Intervention: Differences in postprandial insulin between breakfasts
Number of subjects: 16
Study: 27406142

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP) - 4 × 5 min 220 mmHg bilateral upper leg occlusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CON) - 4 × 5 min 50 mmHg bilateral occlusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 11
Study: 25417983

Group type: EXPERIMENTAL
Intervention: Vicarious error management training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional procedural-based instruction
Number of subjects: 22
Study: 22621799

Group type: EXPERIMENTAL
Intervention: Ranolazine plus amiodarone (group A + R)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amiodarone alone (group A)
Number of subjects: 51
Study: 19834635

Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 66
Study: 17511759

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL, 8 infusions at 4 mg during the first 12 months after LT), calcium (1000 mg/d), and vitamin D (800 IE/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Calcium (1000 mg/d) and vitamin D (800 IE/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 96
Study: 15660089

Group type: EXPERIMENTAL
Intervention: Pilocarpine (Salagen) tablets, escalating doses of 2.5 mg to 5 mg or 5 mg to 7.5 mg qid for 6 weeks, followed by placebo qid for a 2-week washout period
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12501875

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10070908

Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (1.25 mg orally once daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High-dose ramipril (10 mg orally once daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7585845

Group type: EXPERIMENTAL
Intervention: Cefodizime 1 g IM once daily (group A)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cefodizime 1 g IM twice daily (group B)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g IM once daily (group C)
Number of subjects: 298
Study: 2178391

Group type: EXPERIMENTAL
Intervention: Fructose preload
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspartame preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain water control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose preload
Number of subjects: 0
Study: 261517

Group type: EXPERIMENTAL
Intervention: Orally applied hog pancreatic kallikrein
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (normotensive subjects on low sodium diet)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (patients with borderline hypertension on low sodium diet)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (patients with sustained hypertension on low sodium diet)
Number of subjects: 67
Study: 29790804

Group type: EXPERIMENTAL
Intervention: Wartner (cryotherapy compound containing dimethyl ether 75% and propane 25%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Liquid nitrogen (control)
Number of subjects: 16
Study: 28851320

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 80
Study: 25897762

Group type: EXPERIMENTAL
Intervention: Person-centered care planning intervention involving intensive staff training and 12 months of ongoing technical assistance.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 280
Study: 23410994

Group type: EXPERIMENTAL
Intervention: Skills to fuel the body lesson, goal setting, and research snippets
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Lessons on body size and eating enjoyment, and suggested weekly activities
Number of subjects: 653
Study: 21466991

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2-4%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane (1-2%)
Number of subjects: 40
Study: 19736898

Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg bolus followed by 1 mg h(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (i.v. saline)
Number of subjects: 80
Study: 18177192

Group type: EXPERIMENTAL
Intervention: Surgeons' subjective evaluations of facial form for the need for lip revision surgery
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Surgeons' recommendations for revision based on prerevision and postrevision views
Number of subjects: 21
Study: 15030537

Group type: EXPERIMENTAL
Intervention: Dialysis with acetate solution
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dialysis with bicarbonate solution
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with DH
Number of subjects: 63

Group type: COMPARATOR
Intervention: Patients without DH
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 63
Study: 11486253

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg titrated to 300 mg)
Number of subjects: 52
Study: 10687337

Group type: EXPERIMENTAL
Intervention: Morphine sulfate and dextromethorphan hydrobromide (MS:DM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine sulfate (MS) alone
Number of subjects: 0
Study: 8721977

Group type: EXPERIMENTAL
Intervention: CYCLO 3 FORT
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 1992551

Group type: EXPERIMENTAL
Intervention: DL‐3‐hydroxybutyrate (3‐OHB) at a rate of 25 mumol/kg/min for 3 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium DL‐lactate at the same rate as the control subjects
Number of subjects: 20
Study: 6882809

Group type: EXPERIMENTAL
Intervention: Warm-relax (WR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cool-relax (CR)
Number of subjects: 16
Study: 30677175

Group type: EXPERIMENTAL
Intervention: Beyond Good Intentions (BGI) self-management programme
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 108
Study: 29305456

Group type: EXPERIMENTAL
Intervention: Soap irrigation solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline irrigation solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low irrigation pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low irrigation pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High irrigation pressure
Number of subjects: 0
Study: 26315303

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc) for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 48
Study: 24393852

Group type: EXPERIMENTAL
Intervention: Dinaciclib at 50 mg/m², administered as a 2-hour infusion every 21 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Capecitabine at 1250 mg/m², administered orally twice daily in 21-day cycles
Number of subjects: 30
Study: 22668798

Group type: EXPERIMENTAL
Intervention: LPD 7/7
Number of subjects: 38

Group type: COMPARATOR
Intervention: LPD 6/7
Number of subjects: 38
Study: 20842129

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel, cisplatin, 5-fluorouracil)
Number of subjects: 358

Group type: COMPARATOR
Intervention: PF (cisplatin, 5-fluorouracil)
Number of subjects: 358
Study: 17490968

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation (60,000 microg to mothers and 7500 microg to infants)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Lower-dose vitamin A supplementation (60,000 microg to mothers and 15,000 microg to infants)
Number of subjects: 780
Study: 16170938

Group type: EXPERIMENTAL
Intervention: Touch screen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rotary encoder
Number of subjects: 120
Study: 11823395

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 10
Study: 10651974

Group type: EXPERIMENTAL
Intervention: rhDNase therapy (Pulmozyme(R)) over a 6-month period
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: rhDNase therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: rhDNase therapy for subgroup of patients with moderate lung disease
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: rhDNase therapy for subgroup of patients
Number of subjects: 1
Study: 7675044

Group type: EXPERIMENTAL
Intervention: Cardiac-index group
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Oxygen-saturation group
Number of subjects: 762

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (targets reached) - Cardiac-index group
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (targets reached) - Oxygen-saturation group
Number of subjects: 762

Group type: COMPARATOR
Intervention: Subgroup analysis (targets reached) - Control group
Number of subjects: 762
Study: 2147637

Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg day‐1
Number of subjects: 36
Study: 31258137

Group type: EXPERIMENTAL
Intervention: 1-day clear liquid diet (CLD) + polyethylene glycol and electrolyte lavage solution (PEG-ELS)
Number of subjects: 506

Group type: COMPARATOR
Intervention: 3-day combined diet (CMD) + polyethylene glycol and electrolyte lavage solution (PEG-ELS)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: 1-day clear liquid diet (CLD) + sulfate free polyethylene glycol and electrolyte lavage solution (SF-PEG-ELS)
Number of subjects: 506

Group type: COMPARATOR
Intervention: 3-day combined diet (CMD) + sulfate free polyethylene glycol and electrolyte lavage solution (SF-PEG-ELS)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 506

Group type: COMPARATOR
Intervention: SF-PEG-ELS users
Number of subjects: 506
Study: 30092197

Group type: EXPERIMENTAL
Intervention: Narrow-spectrum antibiotics (vancomycin)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (oral vancomycin, ciprofloxacin, metronidazole)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No antibiotics (control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study: 26946732

Group type: EXPERIMENTAL
Intervention: Bloodletting pricking, cupping, and surrounding acupuncture treatment, given once a day and once every other day after the first 3 days for a total of one week.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous drip of acyclovir and oral administration of vitamin B1 and B12, once a day for a total of one week.
Number of subjects: 60
Study: 24145204

Group type: EXPERIMENTAL
Intervention: Multi-level intervention including fundamental movement skill sessions, structured activities, staff role modelling, limiting small screen recreation and sedentary time, and an activity promoting physical environment.
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group continued with usual routines.
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Number of subjects: 459
Study: 22763905

Group type: EXPERIMENTAL
Intervention: 5 mL/kg acetated Ringer's solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mL/kg acetated Ringer's solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dehydration
Number of subjects: 10
Study: 21378348

Group type: EXPERIMENTAL
Intervention: S-1 (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: FT (800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-1 (b.i.d. for 14 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 12
Study: 17389005

Group type: EXPERIMENTAL
Intervention: Unopposed oral 17beta‐estradiol
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 16277792

Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (35 g daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control diet (no walnuts)
Number of subjects: 90
Study: 11865838

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10445898

Group type: EXPERIMENTAL
Intervention: Case management and subsidized community services
Number of subjects: 8095

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8095
Study: 7601294

Group type: EXPERIMENTAL
Intervention: Anxiolytic (fludiazepam) for 12 weeks
Number of subjects: 20
Study: 2088109

Group type: EXPERIMENTAL
Intervention: 4 ml mixture including 3 ml of 0.5% bupivacaine, 0.2 mg adrenaline
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 ml mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine
Number of subjects: 20
Study: 440849

Group type: EXPERIMENTAL
Intervention: Decongestant-antihistamine mixture
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 31530561

Group type: EXPERIMENTAL
Intervention: iBox risk prediction score
Number of subjects: 7557
Study: 28602694

Group type: EXPERIMENTAL
Intervention: Prolonged targeted temperature management (TTM) at 33±1°C for 48 hours
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard targeted temperature management (TTM) at 33±1°C for 24 hours
Number of subjects: 82
Study: 25254938

Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin and 50 mg mirabegron daily for 8 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin daily for 8 weeks
Number of subjects: 94
Study: 23388051

Group type: EXPERIMENTAL
Intervention: Coloured cue to highlight written infectious status information in the transfer form
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pre-transfer checklist used by radiology porters
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both interventions applied (coloured cue and pre-transfer checklist)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300
Study: 21503605

Group type: EXPERIMENTAL
Intervention: Alcohol at 0.04% BAC
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Alcohol at 0.075% BAC
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Alcohol at 0.11% BAC
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High threat intensity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Moderate/low threat intensity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Heavier, more problematic drinkers
Number of subjects: 96
Study: 19484846

Group type: EXPERIMENTAL
Intervention: Depression Care Management (DCM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study: 16418054

Group type: EXPERIMENTAL
Intervention: Doctors judging speakers with acquired dysarthria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (matched for age and gender with neurological deficits not affecting speech)
Number of subjects: 0
Study: 12915681

Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined candesartan/spironolactone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Furosemide (20 mg/d)
Number of subjects: 18
Study: 10596522

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT) with concurrent parent sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control (WLC) condition
Number of subjects: 0
Study: 8735854

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral fluticasone propionate 5 mg or 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once daily for 1 year
Number of subjects: 0
Study: 1720846

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 6816333

Group type: EXPERIMENTAL
Intervention: Home blood pressure recording
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clinic blood pressure recording
Number of subjects: 57
Study: 30314712

Group type: EXPERIMENTAL
Intervention: Individualised duration of elastic compression therapy
Number of subjects: 865

Group type: COMPARATOR
Intervention: Standard duration of elastic compression therapy
Number of subjects: 865